Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00250991
Recruitment Status : Completed
First Posted : November 9, 2005
Last Update Posted : May 8, 2009
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:
University of Cincinnati

Brief Summary:
The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.

Condition or disease Intervention/treatment Phase
Stroke Drug: activase Drug: integrilin Phase 1 Phase 2

Detailed Description:

The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) trial is part of the Specialized Program on Translational Research in Acute Stroke (SPOTRIAS). The overall goals of SPOTRIAS are to enhance delivery of acute stroke patient care and train acute stroke translational researchers.

Stroke most often occurs when blood flow to the brain stops because it is blocked by a blood clot. When a blood clot blocks the blood supply to the brain, parts of the brain may not get enough blood and oxygen to survive. As a result, permanent brain damage can occur, which can affect a person's ability to walk, talk, and function independently. In order to reduce the risk of permanent damage, it is important to restore blood flow to the brain as quickly as possible.

The CLEAR Stroke study will enroll 100 participants with acute stroke due to a blood clot. The purpose of this multi-center, randomized, double-blind study is to determine the effects of using a combination of two drugs, integrilin (or eptifibatide) and activase (or recombinant tissue plasminogen activator, rt-PA, recombinant t-PA), to dissolve blood clots. More specifically, the CLEAR study is being done to determine if a lower dose of activase, given in combination with a second drug, integrilin, is a safe treatment for acute stroke.

Activase, used alone, is already approved by the Food and Drug Administration (FDA) as treatment for patients with a stroke caused by blockage of an artery in the brain and when given within 3 hours of the onset of stroke symptoms. Integrilin is also already FDA-approved as a treatment for blood clots causing heart attack. The investigational aspect of this study is the use of integrilin for a stroke victim in combination with activase.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial
Study Start Date : July 2003
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. The primary safety endpoint in this safety study will be the incidence of symptomatic intracranial hemorrhage . [ Time Frame: within 36 hours ]
  2. The primary measure of early beneficial drug activity will be the incidence of early neurological improvement, as measured by the NIHSSS </= 2 [ Time Frame: at 24 hours from symptom onset ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a serious measurable neurological deficit on the NIH Stroke Scale due to focal brain ischemia.
  • An NIH Stroke Scale score >5 at the time that intravenous study drug is begun.
  • Age: 18 through 80 years (i.e. candidates must have had their 18th birthday, but not had their 81st birthday).
  • Intravenous therapy must be initiated within 3 hours of onset of stroke symptoms.

Exclusion Criteria:

  • History of stroke in the past 3 months.
  • Previous intra-cranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation
  • Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT scan is normal
  • Hypertension at time of treatment; systolic BP > 185 or diastolic > 110 mmHg or aggressive measures to lower blood pressure to below these limits are needed.
  • Presumed septic embolus
  • Presumed pericarditis including pericarditis after acute myocardial infarction
  • Recent (within 30 days) surgery or biopsy of parenchymal organ
  • Recent (within 30 days) trauma, with internal injuries or ulcerative wounds
  • Recent (within 90 days) severe head trauma or head trauma with loss of consciousness
  • Any active or recent (within 30 days) serious systemic hemorrhage
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; or oral anticoagulant therapy with prothrombin time greater than 15 or INR > 1.4
  • Baseline lab values: positive urine pregnancy test, glucose < 50 or > 400 mg/dl, platelets <100,000 /mm3, Hct <25 %, or creatinine > 4 mg/dl
  • Ongoing renal dialysis, regardless of creatinine
  • If heparin has been administered within 48 hours, the patient must have a normal partial thromboplastin time (PTT)
  • Arterial puncture at a non-compressible site or a lumbar puncture in the previous 7 days
  • Seizure at onset of stroke
  • Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations
  • Other serious, advanced, or terminal illness or any other condition that the investigator feels would pose a significant hazard to the patient if rt-PA or eptifibatide therapy were initiated
  • Patients whose peripheral venous access is so poor that they are unable to have two standard peripheral Intravenous lines started.
  • Current participation in another research drug treatment protocol. Patient cannot start another experimental agent until after 90 days
  • Informed consent is not or cannot be obtained
  • Any known history of amyloid angiopathy.

Exclusion Criteria/CT Scan:

  • High density lesion consistent with hemorrhage of any degree.
  • Significant mass effect with midline shift.
  • Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT scan. Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00250991

United States, Arizona
Barrow Neurologic Institute, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd
Phoenix, Arizona, United States, 85013
United States, California
University of California, Los Angeles, UCLA Medical Center, 10833 Le Conte Ave.
Los Angeles, California, United States, 90024
Santa Monica-UCLA Medical Center, 1250 16th Street
Santa Monica, California, United States, 90404
St. John's Health Center, 1328 22nd St
Santa Monica, California, United States, 90404
United States, Kentucky
St. Elizabeth Medical Center South, One Medical Village Drive
Edgewood, Kentucky, United States, 41017
Jewish Hospital Louisville, Jewish Hospital Healthcare Services Inc., 200 Abraham Flexner Way
Louisville, Kentucky, United States, 40202
United States, Michigan
University of Michigan, University of Michigan Health System, 1500 E. Medical Center Drive, TC B1354, Box 0303
Ann Arbor, Michigan, United States, 48109-0303
United States, New York
Long Island Jewish, North Shore-Long Island Jewish Health System, 270-05 76 Avenue
New Hyde Park, New York, United States, 11040
United States, Ohio
The Christ Hospital, 2139 Auburn Ave.
Cincinnati, Ohio, United States, 45219
University of Cincinnati, University Hospital, 234 Goodman Ave.
Cincinnati, Ohio, United States, 45219
Good Samaritan Hospital, 375 Dixmyth Ave.,
Cincinnati, Ohio, United States, 45220-2489
The Jewish Hospital of Cincinnati, 4777 East Galbraith Rd,
Cincinnati, Ohio, United States, 45236
Mercy Hospital, Western Hills, 3131 Queen City Ave.
Cincinnati, Ohio, United States, 45238
Mercy Hospital, Mt Airy, 2446 Kipling Ave.
Cincinnati, Ohio, United States, 45239
Bethesda North Hospital, 10500 Montgomery Rd
Montgomery, Ohio, United States, 45242
United States, Pennsylvania
Lehigh Valley Hospital, 1200 South Cedar Crest Blvd
Allentown, Pennsylvania, United States, 18103
University of Pennsylvania, University of Pennsylvania Medical Center, 3400 Spruce Street
Philadelphia, Pennsylvania, United States, 19104
United States, Rhode Island
Brown University, Rhode Island Hospital, 593 Eddy St.
Providence, Rhode Island, United States, 02903
United States, Tennessee
Vanderbilt University, University Hospital, 1211 22nd Ave. S.
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
University of Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Arthur Pancioli, MD University of Cincinnati College of Medicine, Department of Emergency Medicine

Responsible Party: Arthur Pancioli, MD, University of Cincinnati College of Medicine, Department of Emergency Medicine Identifier: NCT00250991     History of Changes
Other Study ID Numbers: P50NS044283 ( U.S. NIH Grant/Contract )
First Posted: November 9, 2005    Key Record Dates
Last Update Posted: May 8, 2009
Last Verified: May 2009

Keywords provided by University of Cincinnati:
recombinant tissue plasminogen activator
recombinant t-PA

Additional relevant MeSH terms:
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Tissue Plasminogen Activator
Platelet Aggregation Inhibitors
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action